Lupin Q2 Results: Net profit soars 74% YoY to Rs 853 crore on strong demand for generic drugs

November 7, 2024

Lupin exceeded profit expectations in the second quarter, reporting a 74% surge in profits, reaching ₹8.53 billion. This growth was fueled by robust demand for their respiratory and diabetes medications. Overall revenue also saw an 11.3% increase, reaching ₹54.97 billion.

More To Explore

ITC and Cochin Shipyard among stocks that Quant Mid Cap Fund bought and sold in May

Quant Mid Cap Fund added ITC, Lupin, and Aditya Birla Lifestyle Brands to its portfolio in May, while exiting Cochin Shipyard, BHEL, and Ipca Labs.

June 19, 2025

Eternal and Vedanta among stocks which Edelweiss Mutual Fund bought and sold in May

Edelweiss Mutual Fund adjusted its portfolio in May. The Radhika Gupta-led fund increased its stake in HDFC Bank, Reliance Industries and others. It reduced holdings

June 19, 2025

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003